Xeropharmaceuticals Inc., a medical device maker, is seeking to capitalize on the soaring popularity of a new HIV treatment that combines an antiviral medication with a drug to treat anxiety.The drug, called Xerofloxacin, or FLL, has been approved by the Food and Drug Administration in the U.S. and Europe and is being tested in Africa